It was observed that there were significant improvements of dyslipidaemia, hepatic fat fractions and serum markers of liver fibrosis in patients with non-alcoholic steatohepatitis (NASH) with administration of FGF21 (121). This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.